Payment overview · 2025
General Payments
$887.30
23 reported records · 9 companies
Healthcare provider profile · identity verified
Melchor P Cardenas, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAREDO, TX · NPI 1366423725
Verified facts
What the public records show
CMS Open Payments records show Melchor P Cardenas, MD received $887.30 in general payments during 2025 across 23 reported records.
AstraZeneca Pharmaceuticals LP accounted for 62.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $550.92 | 62.1% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $143.14 | 16.1% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $54.35 | 6.1% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $52.00 | 5.9% | 3 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.15 | 2.4% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.07 | 2.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.76 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.50 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.41 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $887.30 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $241.21 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $167.17 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $143.14 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $142.54 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $68.76 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $54.35 | 3 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | SANOFI PASTEUR INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 104 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 163 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
104 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
84 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
163 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
47 | 24 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
84 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1510 | 572 |
| Enalapril Maleate | Enalapril Maleate | 656 | 245 |
| Metformin Hcl | Metformin Hcl | 567 | 206 |
| Amlodipine Besylate | Amlodipine Besylate | 476 | 172 |
| Gabapentin | Gabapentin | 439 | 156 |
| Levothyroxine Sodium | Levothyroxine Sodium | 424 | 140 |
| Losartan Potassium | Losartan Potassium | 366 | 129 |
| Naproxen | Naproxen | 340 | 113 |
| Alendronate Sodium | Alendronate Sodium | 331 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 317 | 98 |
| Clopidogrel | Clopidogrel Bisulfate | 305 | 134 |
| Tamsulosin Hcl | Tamsulosin Hcl | 298 | 107 |
| Furosemide | Furosemide | 290 | 84 |
| Fluticasone Propionate | Fluticasone Propionate | 274 | 119 |
| Simvastatin | Simvastatin | 273 | 83 |
| Lisinopril | Lisinopril | 248 | 102 |
| Montelukast Sodium | Montelukast Sodium | 242 | 83 |
| Zolpidem Tartrate | Zolpidem Tartrate | 242 | 37 |
| Famotidine | Famotidine | 237 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 82 |
| Sertraline Hcl | Sertraline Hcl | 211 | 75 |
| Tramadol Hcl | Tramadol Hcl | 210 | 40 |
| Trazodone Hcl | Trazodone Hcl | 207 | 76 |
| Donepezil Hcl | Donepezil Hcl | 197 | 50 |
| Omeprazole | Omeprazole | 191 | 76 |
| Pioglitazone Hcl | Pioglitazone Hcl | 190 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 66 |
| Ozempic | Semaglutide | 163 | 45 |
| Glipizide Er | Glipizide | 159 | 68 |
| Alprazolam | Alprazolam | 156 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 60 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 137 | 24 |
| Meloxicam | Meloxicam | 130 | 34 |
| Glipizide | Glipizide | 124 | 55 |
| Diclofenac Sodium | Diclofenac Sodium | 122 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 38 |
| Lorazepam | Lorazepam | 114 | 20 |
| Januvia | Sitagliptin Phosphate | 111 | 48 |
| Meclizine Hcl | Meclizine Hcl | 105 | 50 |
| Farxiga | Dapagliflozin Propanediol | 104 | 44 |
| Eliquis | Apixaban | 101 | 27 |
| Pregabalin | Pregabalin | 100 | 21 |
| Finasteride | Finasteride | 98 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 37 |
| Clonazepam | Clonazepam | 94 | 13 |
| Ibuprofen | Ibuprofen | 90 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 29 |
| Jardiance | Empagliflozin | 88 | 32 |
| Mirtazapine | Mirtazapine | 88 | 37 |
| Carvedilol | Carvedilol | 87 | 36 |
| Rexulti | Brexpiprazole | 84 | 16 |
| Clonidine Hcl | Clonidine Hcl | 81 | 20 |
| Nifedipine Er | Nifedipine | 74 | 25 |
| Potassium Chloride | Potassium Chloride | 74 | 20 |
| Levetiracetam | Levetiracetam | 71 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 20 |
| Fanapt | Iloperidone | 64 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 61 | 34 |
| Myrbetriq | Mirabegron | 59 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 57 | 25 |
| Lactulose | Lactulose | 56 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 33 |
| Glimepiride | Glimepiride | 54 | 22 |
| Telmisartan | Telmisartan | 54 | 23 |
| Tradjenta | Linagliptin | 52 | 19 |
| Divalproex Sodium | Divalproex Sodium | 51 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 14 |
| Rybelsus | Semaglutide | 47 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Cilostazol | Cilostazol | 44 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 43 | 13 |
| Ezetimibe | Ezetimibe | 41 | 18 |
| Labetalol Hcl | Labetalol Hcl | 41 | 16 |
| Candesartan Cilexetil | Candesartan Cilexetil | 40 | 11 |
| Cephalexin | Cephalexin | 40 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 15 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 39 | 17 |
| Allopurinol | Allopurinol | 38 | 16 |
| Clotrimazole | Clotrimazole | 38 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 14 |
| Linzess | Linaclotide | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 31 |
| Solifenacin Succinate | Solifenacin Succinate | 36 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 35 | 15 |
| Memantine Hcl | Memantine Hcl | 34 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Belsomra | Suvorexant | 33 | 15 |
| Ramipril | Ramipril | 33 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | 17 |
| Spironolactone | Spironolactone | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 27 |
| Mounjaro | Tirzepatide | 31 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 30 | 12 |
| Atenolol | Atenolol | 30 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | 14 |
| Baclofen | Baclofen | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 25 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | 12 |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | 14 |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Haloperidol | Haloperidol | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | 11 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Xifaxan | Rifaximin | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Misoprostol | Misoprostol | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | 12 |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 14 |
| Risperidone | Risperidone | 19 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | 11 |
| Lovastatin | Lovastatin | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Olanzapine | Olanzapine | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 12 |
| Irbesartan | Irbesartan | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 11 |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Calcitriol | Calcitriol | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Glucagon Emergency Kit | Glucagon | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Loteprednol Etabonate | Loteprednol Etabonate | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | 11 |
| Lumigan | Bimatoprost | 12 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 12 |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $887.30 · 23 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BEYFORTUS, BREZTRI, FARXIGA, GEMTESA, MENQUADFI, OTEZLA, Ozempic, PYRUKYND, REPATHA, REXULTI, VAXELIS, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error